News
Read all about it
For general press and media enquiries about Mesothelioma UK, please contact Simon Gribbon on 07990 583371 or email simon@sandstarcomms.com. If you would like your latest news story or press release to be published in our latest news section below, please send details to meso@sandstarcomms.com for consideration.
CEO visits asbestos monitor and detector manufacturers, Alert Technology Ltd
Mesothelioma UK Chief Executive, Liz Darlison, recently visited Alert Technology Ltd, developers and manufacturers of the world’s first and only...
New Clinical Nurse Specialist appointed to support patients in Essex
Sam Jayasekara has been appointed as a Mesothelioma UK Clinical Nurse Specialist (CNS) to provide nursing care and support for mesothelioma patients...
Donation received from RS Oncology
RS Oncology, a clinical stage biotechnology company based in Cambridge, Massachusetts in the US, donated to Mesothelioma UK to support the charity’s...
New Clinical Nurse Specialist appointed to support asbestos-related cancer patients in Northumbria
Helen Wallace has been appointed as a Mesothelioma UK Clinical Nurse Specialist to provide nursing care and support for mesothelioma...
MITOPE clinical trial brings a new treatment to patients suffering from Malignant Pleural Effusion and Malignant Mesothelioma
15% of cancer patients develop pleural effusion as their disease spreads to the lungs and accumulates excess fluid and this condition is common...
Targeted cancer treatment could provide new hope for mesothelioma patients
Researchers at the Cancer Research UK Southampton Clinical Trials Unit and the University of Leicester are running the NERO trial (Niraparib...
Introducing the new Health Companion portal
Working in collaboration with DaSH-Global, a real-world research company specialising in healthcare, we have developed a new digital patient app...
A call for urgent change to improve outcomes for patients with asbestos-related cancer
Mesothelioma UK has launched the Uncovering Mesothelioma report, published by the pharmaceutical company, Bristol Myers Squibb to coincide with...
Join our Asbestos Commercial Club
If you are a business involved in the management of asbestos or the diseases it causes, why not join our Asbestos Commercial Club (MUKACC) to...
CEO Liz Darlison to speak at the European Asbestos Conference
Mesothelioma UK’s CEO, Liz Darlison, has been confirmed as a speaker at the European Asbestos Forum Conference (EAF). The event will take place from...
CEO visits asbestos monitor and detector manufacturers, Alert Technology Ltd
Mesothelioma UK Chief Executive, Liz Darlison, recently visited Alert Technology Ltd, developers and manufacturers of the world’s first and only range of real-time airborne asbestos monitor and detectors. Alert Technology wrote this piece about the visit: Liz Darlison...
New Clinical Nurse Specialist appointed to support patients in Essex
Sam Jayasekara has been appointed as a Mesothelioma UK Clinical Nurse Specialist (CNS) to provide nursing care and support for mesothelioma patients in Essex. The post is funded by asbestos disease support charity, HASAG. Sam will be based at the Broomfield Hospital...
Donation received from RS Oncology
RS Oncology, a clinical stage biotechnology company based in Cambridge, Massachusetts in the US, donated to Mesothelioma UK to support the charity’s Clinical Nurse Specialist team. Liz Darlison, CEO of Mesothelioma UK added: “Our network of over 30 Clinical Nurse...
New Clinical Nurse Specialist appointed to support asbestos-related cancer patients in Northumbria
Helen Wallace has been appointed as a Mesothelioma UK Clinical Nurse Specialist to provide nursing care and support for mesothelioma (asbestos-related cancer) patients in the area. The post is funded by Mesothelioma UK and Helen will be based at the Wansbeck Hospital...
Targeted cancer treatment could provide new hope for mesothelioma patients
Researchers at the Cancer Research UK Southampton Clinical Trials Unit and the University of Leicester are running the NERO trial (Niraparib Efficacy in patients with unResectable MesotheliOma) to test whether a type of drug called a PARP inhibitor could be an...